These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 20818440)
21. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Hostein I; Andraud-Fregeville M; Guillou L; Terrier-Lacombe MJ; Deminière C; Ranchère D; Lussan C; Longavenne E; Bui NB; Delattre O; Coindre JM Cancer; 2004 Dec; 101(12):2817-24. PubMed ID: 15536621 [TBL] [Abstract][Full Text] [Related]
22. Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. Oue T; Yoneda A; Uehara S; Yamanaka H; Fukuzawa M J Pediatr Surg; 2010 Feb; 45(2):387-92. PubMed ID: 20152358 [TBL] [Abstract][Full Text] [Related]
23. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice. van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124 [TBL] [Abstract][Full Text] [Related]
24. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Ahn EH; Mercado GE; Laé M; Ladanyi M Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015 [TBL] [Abstract][Full Text] [Related]
30. Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma. Krsková L; Mrhalová M; Hilská I; Sumerauer D; Drahokoupilová E; Múdry P; Kodet R Virchows Arch; 2010 May; 456(5):463-72. PubMed ID: 20405298 [TBL] [Abstract][Full Text] [Related]
31. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas. Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794 [TBL] [Abstract][Full Text] [Related]
37. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931 [TBL] [Abstract][Full Text] [Related]
38. Close correlation between CXCR4 and VEGF expression and frequent CXCR7 expression in rhabdomyosarcoma. Miyoshi K; Kohashi K; Fushimi F; Yamamoto H; Kishimoto J; Taguchi T; Iwamoto Y; Oda Y Hum Pathol; 2014 Sep; 45(9):1900-9. PubMed ID: 25086956 [TBL] [Abstract][Full Text] [Related]
39. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis. Srivastava RK; Kaylani SZ; Edrees N; Li C; Talwelkar SS; Xu J; Palle K; Pressey JG; Athar M Oncotarget; 2014 Dec; 5(23):12151-65. PubMed ID: 25432075 [TBL] [Abstract][Full Text] [Related]
40. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group. Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]